Literature DB >> 31866480

Long-Term Outcomes of Mosaic Versus Perimount Mitral Replacements: 17-Year Follow-Up of 940 Implants.

Tyler J Beute1, Matthew Goehler2, Jessica Parker2, Theodore Boeve3, John Heiser3, Edward Murphy3, Tomasz Timek3, Charles L Willekes4.   

Abstract

BACKGROUND: The objective of this study was to compare long-term outcomes of Mosaic (Medtronic, Minneapolis, MN) porcine mitral valves to Carpentier-Edwards (Edwards Lifesciences, Irving, CA) bovine pericardial mitral valves.
METHODS: From 2001 through 2017 at a single institution, 940 patients received a mitral bioprosthesis, of which 463 (49.3%) were porcine and 477 (50.7%) were bovine pericardial. Retrospective review of the procedure and the postoperative clinical course, including echocardiography, through August 2018 were analyzed. All consecutive mitral valve replacements over the study period were included. Follow-up was 99% (929 patients) complete for a total of 6045 patient-years (mean, 6.4 ± 4.5 years). A propensity-matched cohort of 802 mitral bioprosthesis was used for outcome analyses.
RESULTS: Operative mortality of the 940 patients was 5.4% (n = 51) and incidence of postoperative stroke was 2.1% (n = 20). Overall survival of the propensity-matched patients at 10 and 15 years was 49.7% (95% confidence interval [CI] 45.5%-53.7%) and 23.3% (95% CI 17.9%-29.3%), respectively. Survival at 15 years was 24.0% (95% CI 18.0%-30.5%) for porcine and 16.5% (95% CI 5.5%-32.6%) for bovine implants, which was not significantly different (P = .67). Overall cumulative incidence for reoperative structural valve deterioration at 15 years was 7.9% (95% CI 4.7%-12.3%) for porcine valves versus 13.2% (95% CI 8.1%-19.5%) for pericardial valves (P < .001). For patients age younger than 65 years, structural valve deterioration at 15 years was 15.8% (95% CI 7.4%-27.0%) versus 30.2% (95% CI 15.1%-46.8%) for porcine and pericardial valves, respectively (P = .009). Overall average time to reoperation for structural valve deterioration for porcine valves was 11.1 ± 2.3 years vs 6.8 ± 2.3 years for bovine pericardial valves (P < .001).
CONCLUSIONS: In long-term follow-up, of patients younger than 65 years of age undergoing mitral valve replacement, bovine pericardial valves experienced earlier and more frequent structural valve deterioration than porcine valves.
Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31866480     DOI: 10.1016/j.athoracsur.2019.10.075

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Prosthetic cardiac valves: history and review of cardiac prostheses clinically available in Japan.

Authors:  Eiki Tayama; Kosuke Saku; Tomoyuki Anegawa; Atsunobu Oryoji; Shinya Negoto
Journal:  Surg Today       Date:  2021-08-25       Impact factor: 2.549

2.  Comparative analysis of structural valve deterioration and long-term clinical outcomes after bovine pericardial versus porcine bioprosthetic mitral valve replacement.

Authors:  Woojung Kim; Ho Young Hwang; Yoonjin Kang; Ji Seong Kim; Suk Ho Sohn; Jae Woong Choi; Kyung Hwan Kim
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

Review 3.  Regulatory Role of Sex Hormones in Cardiovascular Calcification.

Authors:  Holly J Woodward; Dongxing Zhu; Patrick W F Hadoke; Victoria E MacRae
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

4.  Comparison of a new bioprosthetic mitral valve to other commercially available devices under controlled conditions in a porcine model.

Authors:  Dee Dee Wang; Thomas G Caranasos; Brian P O'Neill; Richard S Stack; William W O'Neill; W Randolph Chitwood
Journal:  J Card Surg       Date:  2021-10-05       Impact factor: 1.778

5.  Heart team approach in treatment of mitral regurgitation: patient selection and outcome.

Authors:  Mischa Külling; Roberto Corti; Georg Noll; Silke Küest; David Hürlimann; Christophe Wyss; Ivano Reho; Felix C Tanner; Jeremy Külling; Nicolai Meinshausen; Oliver Gaemperli; Peter Wenaweser; Sacha P Salzberg; Thierry Aymard; Jürg Grünenfelder; Patric Biaggi
Journal:  Open Heart       Date:  2020-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.